Pharmaceutical drug refers to a substance created to treat, prevent, or cure an illness or other condition, or to lessen its symptoms. To list the most popular methods, drugs can be consumed orally, through a skin patch, by injection, or through an inhaler. Other vital medications made from natural materials include vaccinations, steroid hormones, human blood-plasma fractions, and antibiotics. The main types of pharmaceutical drugs are cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorders drugs, musculoskeletal disorders drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs. Cardiovascular drugs are used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The pharmaceutical drug market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical drug market statistics, including pharmaceutical drug industry global market size, regional shares, competitors with a pharmaceutical drug market share, detailed pharmaceutical drug market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical drug industry. This pharmaceutical drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical drugs market is expected to grow from $ 1,136.23 billion in 2022 to $1,199.86 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The pharmaceutical drugs market is expected to reach $1,848.49 billion in 2027 at a CAGR of 11.4%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. China and India together had about 193.4 million diabetic patients in 2019 and India is expected to have about 101 million diabetic patients by 2030, thereby increasing the need for biologics drugs for diabetic patients. These factors are expected to increase the patient pool globally, thereby driving the pharmaceutical drug market during the forecast period. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period, this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research, and development of new products. For instance, the US interest rates rose to 3.5% by 2021. These factors are expected to hurt the market as borrowing money becomes expensive, thereby affecting the pharmaceuticals market growth. Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company. For example, in 2020, FDA has switched three prescription drugs to OTC including Voltaren for arthritis pain, olopatadine hydrochloride 0.1% and 0.2% (Pataday Twice Daily Relief and Pataday Once Daily Relief) for temporary relief of itchy and red eyes due to pollen, ragweed, and grass. Major companies in the pharmaceutical drugs market include Bristol-Myers Squibb, Sanofi S.A, Johnson & Johnson, Novartis AG, Bayer AG, Abbott Laboratories, GlaxosmithKline, AstraZenec, Merck & Co and CJ Corp. North America was the largest region in the pharmaceutical drugs market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The pharmaceutical drug market consists of sales of generic drugs, over-the-counter medications, bulk drugs, vaccines, biosimilars, and biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical drugs market is segmented - 1) By Type: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs), Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases, Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals, Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs For Infections And Others, Drugs For Hormonal Replacement Therapy, Diuretics, Blood Products, Anemia And Other Blood Disorder Drugs, Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal), Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism), Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs, Analgesics, Anti-Parkinson drugs, Anesthetics, Anti-Epileptics, Other CNS drugs, Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma), Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy), Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations

Generic pharmaceuticals refer to a drug that was developed to have the same dosage form, safety, strength, mode of administration, quality, performance attributes, and intended use as an already marketed brand-name drug. The action and clinical benefits of a generic drug are identical to those of a brand-name drug. The three main types of generic pharmaceuticals are biosimilar; simple generic, and super generic. A biosimilar is a biological product that is very similar to a reference biologic and has no clinically significant differences in terms of safety, purity, or potency. The drugs are delivered through oral, injectable, dermal/topical, and inhalers that are used for various therapies such as CNS, cardiovascular, dermatology, genitourinary/hormonal, respiratory, rheumatology, diabetes, and oncology. The various distribution channels involved is hospital pharmacies, retail pharmacies, and online pharmacies. The generic pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides generic pharmaceuticals market statistics, including generic pharmaceuticals industry global market size, regional shares, competitors with a generic pharmaceuticals market share, detailed generic pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the generic pharmaceuticals industry. This generic pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global generic pharmaceuticals market grew from $332.43 billion in 2022 to $358.5 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The generic pharmaceuticals market is expected to grow from $453.19 billion in 2027 at a CAGR of 6.0%. The rising incidence of chronic diseases is one of the major drivers of the generic pharmaceutical market. As more individuals are diagnosed with chronic diseases, they look for more medicines for treatment. Branded drugs come at a premium price, while generic drugs are available at a lower cost and have the same chemical composition as branded drugs. The low cost and same chemical composition and strength of generic drugs make a patient buy generic drugs instead of branded drugs. If it is a chronic disease, the treatment goes on for a longer period, and hence, the sales of generic drugs also increase. For instance, according to the WHO (World Health Organization), over the next 10 years, the number of deaths due to chronic disease is projected to increase by 17%. Also, in 2020, almost 3-quarters of all deaths in the world are due to chronic diseases. The lack of awareness about generic drugs is one of the restraints on the generic pharmaceutical market. The high marketing and advertisement of branded drugs overshadow the availability of generic drugs, which are a substitute for expensive branded drugs. Thus, consumers opt for branded drugs even though the generic drugs carry the same chemical formulation as their counter-branded drugs. According to an article published on CVS HEALTH, many doctors and pharmacists preferred to offer branded drugs to their patients over generic drugs. This prevents the patients to go for generic drugs as they develop a preconceived notion of generic drugs not being at par with branded drugs. For example, according to research conducted by Sahana K Hebbar, in the International Journal of Basic & Clinical Pharmacology, out of 100 patients and 50 non-medical staff, 95% of the patients and 60% of the non-medical staff didn't know about generic drugs. Thus, a lack of awareness about the availability of generic drugs hampers the generic pharmaceutical market. 3D printing technology can transform the manufacturing of drugs in the generic pharmaceutical market. 3D printed pharmaceuticals help improve R&D productivity and deliver new benefits to patients. 3D printing allows the manufacturer to produce drugs with customised size, shape, and texture, which is not possible in traditional manufacturing of generic drugs. 3D printing can help the manufacturer to make generic drugs that have different release dates, appearances, and tastes. For example, GlaxoSmithKline (GSK) completed a study where ultraviolet (UV) and 3D printing were used to manufacture tablets to treat Parkinson's disease. Martin Wallace, director of GSK Technology, said that GSK is investing in 3D printing to manufacture pills and tablets. Also, Aprecia pharmaceutical company launched 'ZipDose' technology, which manufactures 3D printed drugs. The drug manufacturers must comply with the CGMP (Current Good Manufacturing Practice) regulations that come under the US Food and Drug Administration (FDA) which includes generic pharmaceuticals. The CGMP regulations require manufacturers to maintain a minimum quality standard for the methods, controls, and facilities used in the manufacturing, packaging, and processing of drug products. Part- 99 of chapter 1 under title 21-Food And Drugs of CFR (Code of Federal Regulations) contains subparts from A to H. The whole part-99 describes the guidelines that need to be followed by drug manufacturers regarding the dissemination of information on human drugs, including biologics, and devices. The guidelines concern the safety, effectiveness, or benefit of use that is not included in the approved labelling for a drug or device approved by the Food and Drug Administration for marketing. The guidelines regulate the information regarding the drugs that should be delivered to the health care practitioner, pharmacy benefit manager, health insurance issuer, group health plan, or federal or state government agency. In January 2020, ANI Pharmaceuticals, Inc., a USA-based integrated specialty pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceuticals, acquired Commercial and Pipeline Generic Products from American Pharmaceuticals, Ltd. for $52.5M in cash. This acquisition substantially increases ANI Pharmaceuticals, Inc.’s commercial portfolio and late-stage generic pipeline. Amerigen Pharmaceuticals is a USA-based company focused on the development, manufacture, and sale of high-quality generic pharmaceutical products. Major players in the generic pharmaceuticals market are Teva Pharmaceuticals, Mylan NV, Sandoz International GmbH, Hospira (Pfizer Inc.), Sun Pharmaceutical, Lupin Limited, Endo International PLC., Dr Reddy's Laboratories, Apotex Holdings, Fresenius Kabi Ag, Aurbindo Pharma, Aspen Pharmacare, Sanofi, Cipla, Hikma Pharmaceuticals, Stada Arzneimittel, Krka Group, Nichi-Iko Pharmaceutical, Valeant, Zydus Cadila, Merck & Co., Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Nexus Pharmaceuticals, Novo Nordisk, Ranbaxy Laboratories Ltd., Sawai Pharmaceuticals, Novartis AG, Pfizer and Johnson & Johnson Services. North America was the largest region in the generic pharmaceuticals market in 2022. The Middle East is expected to be the fastest-growing region in the global generic pharmaceuticals market during the forecast period. The regions covered in the global generic pharmaceuticals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the generic pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The generic pharmaceuticals market consists of sales of paracetamol, cefixime, amoxicillin, and ofloxacin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global generic pharmaceuticals market is segmented - 1) By Therapy: CNS, Cardiovascular, Dermatology, Genitourinary/Harmonal, Respiratory, Rheumatology, Diabetes, Oncology 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Type: Biosimilar, Simple Generic, Super Generic 4) By Drug Delivery: Oral, Inectables, Dermal/Topical, Inhaler

Medical equipment are devices that can be instrument, apparatus or machine that can be used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting or modifying the structure or function of the body for health purpose. The main types of medical equipment are in-vitro diagnostics, dental equipment and supplies, ophthalmic devices, diagnostic imaging equipment, cardiovascular devices, hospital supplies, surgical equipment, orthopedic devices, patient monitoring devices, diabetes care devices, nephrology and urology devices, ENT devices, anesthesia and respiratory devices, neurology devices, and wound care devices. In-vitro diagnostics are tests done on samples like blood or tissue that is taken from the human body. In-vitro diagnostics will detect diseases or other conditions and are used to monitor a person’s overall health to cure, treat, or prevent diseases. The type of expenditure involved is public and private. The various product are instruments/equipment and disposables. The various end users involved are hospitals and clinics, homecare, diagnostics centres, and others. The medical equipment market research report is one of a series of new reports from The Business Research Company that provides medical equipment market statistics, including medical equipment industry global market size, regional shares, competitors with a medical equipment market share, detailed medical equipment market segments, market trends and opportunities, and any further data you may need to thrive in the medical equipment industry. This medical equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global medical equipment market grew from $639.75 billion in 2022 to $695.05 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The medical equipment market is expected to grow to $922.39 billion in 2027 at a CAGR of 7.3%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% globally, by the year 2020. This is increasing the demand for medical devices used in the diagnosis, prognosis, and treatment of several diseases, thereby driving the demand for medical equipment. These factors are expected to increase the patient pool globally, thereby driving the market during the forecast period. Regulatory changes are likely to lead to increased costs relating to new product development and service offerings to clients. These changes are related to customer data protection such as the European Union's General Data Protection Regulation (GDPR), changes to equipment approval procedures, and other regulatory changes. For instance, according to cookieyed data 2021, in the US, PwC reported that 68% of 200 businesses surveyed intended to spend between $1 million and $10 million to comply with GDPR regulations. The GDPR regulation is an EU law on data protection and privacy of individuals residing in the European Union and the European Economic Area (EEA). It also regulates the export of personal data outside the EU and EEA areas. Additionally, the FDA is requesting more clinical data to support claims, therefore increasing the time to process 510(k)s by over 55% over the last decade. The potential loss of revenue due to delays in product release and additional costs incurred due to stringent approval processes puts a strain on investments relating to new product development, thereby affecting the growth of the medical equipment market. Device performance and patient data are available to healthcare service providers and are helping them to improve patient monitoring and overall care quality. Some companies are integrating medical device data with EMR (Electronic Medical Records) to improve transparency and collaboration. As consumer wearables are becoming more common, patient data volumes are increasing and companies are investing in deploying data management, warehousing, and security technologies. For example, Medtronic launched a tool to augment their cardiac devices to securely transfer device data to doctors and allow them to monitor the critical health indicators of their patients. Major companies in the medical equipment market include Medtronic Inc., Abbott Laboratories, Johnson & Johnson, Cardinal Health, Inc., Becton Dickinson, Siemens AG, STRYKER CORPORATION, Koninklijke Philips N.V., F. Hoffmann-La Roche Ltd., and Boston Scientific Corporation. North America was the largest region in the global medical equipment market in 2022. Asia-Pacific was the second largest region in the global medical equipment market. The regions covered in the medical equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the medical equipment market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The medical equipment market consists of sales of devices used in the diagnosis, treatment and monitoring of medical conditions. The market includes diagnostic devices, imaging devices, surgical devices and patient monitoring devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global medical equipment market is segmented - 1) By Type: In-Vitro Diagnostics, Dental Equipment And Supplies, Ophthalmic Devices, Diagnostic Imaging Equipment, Cardiovascular Devices, Hospital Supplies, Surgical Equipment, Orthopedic Devices, Patient Monitoring Devices, Diabetes Care Devices, Nephrology And Urology Devices, ENT Devices, Anesthesia And Respiratory Devices, Neurology Devices, Wound Care Devices 2) By Type of Expenditure: Public, Private 3) By Product: Instruments/Equipment, Disposables 4) By End User: Hospitals And Clinics, Homecare, Diagnostics Centers, Other End Users Subsegments Covered: Point-of-Care Diagnostics Devices And Equipment, Immunochemistry Diagnostic Devices And Equipment, Clinical Chemistry Diagnostics Devices And Equipment, Molecular Diagnostics Devices And Equipment, Microbiology Diagnostic Devices And Equipment, Hemostasis Diagnostic Devices And Equipment, Hematology Diagnostic Devices And Equipment, Immunohematology Diagnostic Devices And Equipment, Therapeutic Dental Equipment, General Dental Devices And Equipment, Dental Diagnostic Imaging Devices And Equipment, Dental Surgical Devices And Equipment, Vision Care Devices And Equipment, Cataract Surgery Devices And Equipment, Refractive Surgery Devices And Equipment, Diagnostic And Monitoring Ophthalmic Devices And Equipment, X-Ray Systems Devices And Equipment, Ultrasound Systems Devices And Equipment, Computed Tomography (CT) Scanners Devices And Equipment, Magnetic Resonance Imaging Systems Devices And Equipment, Cardiovascular Monitoring And Diagnostic Devices And Equipment, Nuclear Imaging Devices And Equipment, Cardiovascular Surgery Devices And Equipment, Cardiac Rhythm Management (CRM) Devices And Equipment, Interventional Cardiology Devices And Equipment, Defibrillator Devices And Equipment, Peripheral Vascular Devices And Equipment, Prosthetic Heart Valve Devices And Equipment, Electrophysiology Devices And Equipment, Cardiac Assist Devices And Equipment, Disposable Hospital Supplies, Sterilization Equipment And Disinfectants, Mobility Aids And Transportation Equipment, Operating Room Equipment, Surgical Sutures And Staples, Handheld Surgical Devices And Equipment, Electrosurgical Devices And Equipment, Joint Reconstruction Devices And Equipment, Spinal Surgery Devices And Equipment, Trauma Fixation Devices And Equipment, Orthobiologics Devices And Equipment, Arthroscopy Devices And Equipment, Orthopedic Braces And Support Devices And Equipment, Craniomaxillofacial (CMF) Devices And Equipment, Orthopedic Prosthetics, Orthopedic Accessories,, Fetal And Neonatal Monitoring Devices, Weight Monitoring And Body Temperature Monitoring Devices And Equipment, Vital Parameter Monitoring Devices And Equipment, Remote Patient Monitoring Devices And Equipment, Blood Glucose Test Strips, Insulin Pens, Syringes, Pumps And Injectors, Lancing Devices And Equipment, Continuous Glucose Monitoring Devices And Equipment, Blood Glucose Meters, Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment, Hearing Aid Devices And Equipment, Hearing Diagnostic Devices And Equipment, ENT Surgical Devices And Equipment, Hearing Implants, Voice Prosthesis Devices And Equipment, Nasal Splints, Respiratory Devices And Equipment (Therapeutic And Diagnostic), Anesthesia Machines, Anesthesia Disposables, Respiratory Disposables, Cerebrospinal Fluid Management (CSF) Devices And Equipment, Interventional Neurology Devices And Equipment, Neurosurgery Devices And Equipment, Neurostimulation Devices, Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices

Hospital-acquired infections are acquired during hospital care that is not present before hospital admission. The prevention and control of hospital-acquired infection using various cleaning, sterilization, and disinfection methods refers to hospital-acquired infection control. These infections can be caused by the cross-infection from the surfaces of equipment, the skin of patients, and healthcare staff. Hospital-acquired infection control is used to reduce or eliminate the transmission of illnesses. The main types of products in hospital-acquired infection control are sterilizers, disinfectors, endoscope reprocessors, microbial testing instruments, reagents, consumables, disinfectants, infection prevention and surveillance software, and others. Sterilizers refer to a machine for making things entirely clean and bacteria-free. Sterilizers are used to kill germs on an article's surface or in a fluid in order to prevent disease transmission. The different technologies include phenotypic and genotypic methods and involve several types of diseases such as hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections and other diseases. The various applications include disease testing and drug-resistance testing. The end user involved are hospitals, ICUs, ambulatory surgical, diagnostic centres, nursing homes, maternity centres, and others. The hospital-acquired infection control market research report is one of a series of new reports from The Business Research Company that provides hospital-acquired infection control market statistics, including hospital-acquired infection control industry global market size, regional shares, competitors with a hospital-acquired infection control market share, detailed hospital-acquired infection control market segments, market trends and opportunities, and any further data you may need to thrive in the hospital-acquired infection control industry. This hospital-acquired infection control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hospital-acquired infection control market size grew from $31.02 billion in 2022 to $32.09 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hospital-acquired infection control market size is expected to grow to $36.88 billion in 2027 at a CAGR of 3.5%. The surge in COVID-19 cases is expected to propel the growth of the hospital-acquired infection control market going forward. COVID-19 refers to a viral infection that is caused by the SARS-CoV-2 virus. Due to the COVID-19 pandemic, there is an increase in demand for hospital-acquired infection control products and services to focus on personal hygiene and the production of infection control medical supplies. For instance, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, as of 8th August 2022, the global COVID-19 cases reached 581.6 million. Therefore, the surge in COVID-19 cases is driving the growth of the hospital-acquired infection control market. Technological advancements are a key trend gaining popularity in the hospital-acquired infection control market. Major companies operating in the hospital-acquired infection control market are focused on developing new technological solutions to lead the market. For instance, in November 2021, the scientists of University of Pittsburgh School of Medicine and Carnegie Mellon University, used machine learning technology with whole genome sequencing to rapidly detect infectious disease outbreaks in a hospital. Significant outbreaks that might otherwise escape routine infection prevention monitoring are discovered by this method. In June 2021, Steris Corporation, a US-based medical equipment company specializing in sterilization and surgical products acquired Cantel Medical for an undisclosed amount. This acquisition would help Steris to extend product and service offerings as well as global reach. Cantel Medical is a US-based manufacturer of infection prevention products. Major players in the hospital-acquired infection control market are Belimed AG, Advanced Sterilization Products Services Inc., 3M Company, Getinge AB, Olympus Corporation, Ecolab Inc., Steris Healthcare PVT Ltd., MMM Group, Contec Inc., Steelco S.P.A., Miele Group, Sotera Health LLC, Matachana Group, and Reckitt Benckiser Group plc. North America was the largest region in the hospital-acquired infection control market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hospital-acquired infection control report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the hospital-acquired infection control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hospital-acquired infection control market includes revenues earned by entities by heat sterilization equipment, low temperature sterilization equipment, radiation sterilization equipment, other sterilization equipment, contract sterilization services, sterilization consumables and accessories, disinfectants, and disinfectors equipment. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global hospital acquired infection control market is segmented - 1) By Product: Sterilizers, Disinfectors, Endoscope Reprocessors, Microbial Testing Instruments, Consumables, Disinfectants, Infection Prevention And Surveillance Software, Other Products 2) By Technology: Phenotypic Methods, Genotypic Methods 3) By Diseases: Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infection, Other Diseases 4) By Application: Disease Testing, Drug-Resistance Testing 5) By End User: Hospitals, ICUs, Ambulatory Surgical, Diagnostic Centers, Nursing Homes, Maternity Centers, Other End Users

The hospital-acquired infection testing kits are tools used to check the infections people get while in a healthcare facility. Hospital-acquired infections testing kits are used to check the infections associated with pathogens such as vancomycin-resistant enterococci (VRE), methicillin-resistant staphylococcus aureus (MRSA), multi-resistant gram-negative bacilli, norovirus, and Clostridium difficile. The main products of hospital-acquired infection testing kits are instruments, reagents, and consumables. The hospital-acquired infections testing kit instruments involve the various instruments that are required for hospital-acquired infections testing to aid scientists in growing new cells in the culture media for drug development, tissue culture, engineering, gene therapy, vaccine production, and toxicity testing. Pathogens tested using hospital-acquired infections testing kits include viral, bacterial, and fungal pathogens using sterilization, chemical, and radiation methods of treatment to test for pneumonia infection, urinary tract infection, bloodstream infection, surgical site infection, MRSA infection, and others.The various applications include drug-resistance testing and disease testing. The hospital-acquired infections testing kits market research report is one of a series of new reports from The Business Research Company that provides hospital-acquired infections testing kits market statistics, including hospital-acquired infections testing kits industry global market size, regional shares, competitors with a hospital-acquired infections testing kits market share, detailed hospital-acquired infections testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the hospital-acquired infections testing kits industry. This hospital-acquired infections testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hospital acquired infections testing kits market grew from $1.27 billion in 2022 to $1.4 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hospital acquired infections testing kits market is expected to grow from $2 billion in 2027 at a CAGR of 9.4%. The hospital-acquired infections (HAIs) are on the rise, affecting both the inpatients and outpatients. Hospital-acquired infections or nosocomial infections are diseases that are acquired in hospitals and medical clinics. For example, according to the findings by the Center for Disease Control and Prevention, around 1.7 million people in the USA acquire hospital-acquired infections caused while being admitted for other health issues and more than 98,000 (around 5%) patients die due to these infections. The increasing incidence of hospital-acquired infections leads to an increase in the demand for hospital-acquired infections testing kits. Most of the underdeveloped and developing nations lack proper health insurance that covers essential health services. According to a report by the World Bank and the World Health Organization, more than 50% of the world’s population cannot avail of essential health services due to expensive healthcare services that push them to poverty. For instance, 800 million people spend more than 10% of their household budgets on health expenses for themselves, a sick child, or other family members, and for almost 100 million people these expenses are high enough to push them into extreme poverty. This lack of financially affordable healthcare hinders the market growth for diagnostic services including hospital-acquired infection testing. The diagnostic tests involved in diagnosing HAIs such as flow cytometry, mass spectrometry, near-infrared spectroscopy, and nucleic acid-based technologies are advancing in technologies, providing more accurate data. There has been a significant advancement in mass spectrometers, which quantifies known materials, and identifies unknown compounds within a sample. For instance, SCIEX’s X500 QTOF solves the challenge of contamination and is a compact device that does not compromise on resolution and accuracy. It gives results sooner and allows the operator to make data-driven decisions sooner. The hospital-acquired infections testing kits are regulated by government agencies such as US FDA (Food and Drug Administration) in the USA, and the European Medicines Agency/Committee in European Region. The regulatory body lays down a set of guidelines pertaining to the safety, efficiency, and efficacy of the instruments that form part of the hospital-acquired infection testing kits market. The manufacturers and service providers must comply with the CBER Regulations that have been published in the first chapter of Title 21 of CFR. Part 600 of CFR 21 primarily focuses on the established standards like sample retention conditions, temperature to be maintained during shipment, sterilisation of equipment, and the role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. CBER comes under the FDA (Food and Drug Administration). Also, the Code of Federal Regulations, Title 21, Part 866, states regulations pertaining to immunology and microbiology devices. These devices are used to identify infections caused by bacteria and various viruses. Major players in the hospital-acquired infections testing kits market are Becton, Dickinson and Company, Abott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd., Hologic, Roche, Bayer AG, Cantel Medical Corporation, and Meridian Bioscience. North America was the largest region in the hospital-acquired infections testing kits market in 2022. Western Europe was the second largest region in the global hospital-acquired infections testing kits market. The regions covered in the global hospital-acquired infections testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hospital-acquired infections testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The hospital-acquired infections testing kits market consist of sales of testing kits and devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global hospital acquired infections testing kits market is segmented - 1) By Product: Instrument & Reagents, Consumables 2) By Test Type: Pneumonia Infection, Urinary Tract Infection, Blood Stream Associated Infection, Surgical Site Infection, MRSA Infection, Other Test Types 3) By Application: Drug-resistance Testing, Disease Testing 4) By Pathogen Type: Viral, Bacterial, Fungal 5) By Method of Treatment: Sterilization, Chemical, Radiation

Urinary incontinence & pelvic organ prolapse devices and equipment are used in the treatment of pelvic organ prolapse and urinary incontinence. Urinary incontinence (UI), also known as involuntary urination, is defined as uncontrolled leakage of urine caused by an overactive bladder. Pelvic organ prolapse (POP) is caused by defects in the supporting structures of the vagina. The main types in urinary incontinence and pelvic organ prolapse devices and equipment are urinary incontinence devices and pelvic organ prolapse devices. The devices used to treat urinary incontinence are known as urinary incontinence devices. Artificial urinary sphincters, electrical stimulation devices, urethral slings, and catheters are examples of urinary incontinence devices. Vaginal mesh and vaginal pessaries are pelvic organ prolapse devices. The incontinence types are stress incontinence, urge incontinence, overflow incontinence, and functional incontinence. The various end-user involved are hospitals, clinics, ambulatory surgical centres, and home use. The urinary incontinence and pelvic organ prolapse devices and equipment market research report is one of a series of new reports from The Business Research Company that provides urinary incontinence and pelvic organ prolapse devices and equipment market statistics, including urinary incontinence and pelvic organ prolapse devices and equipment industry global market size, regional shares, competitors with urinary incontinence and pelvic organ prolapse devices and equipment market share, detailed urinary incontinence and pelvic organ prolapse devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the urinary incontinence and pelvic organ prolapse devices and equipment industry. This urinary incontinence and pelvic organ prolapse devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global urinary incontinence and pelvic organ prolapse devices and equipment market size will grow from $0.43 billion in 2022 to $0.46 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global urinary incontinence and pelvic organ prolapse devices and equipment market size is expected to grow to $0.59 billion in 2027 at a CAGR of 6.3%. The increased prevalence rate for Pelvic organ prolapse (POP) as well as for urinary incontinence (UI) disorders has been driving the growth of urinary incontinence and pelvic organ prolapse (POP) devices and equipment market. The increasing prevalence rate has led manufacturers towards developing more accurate and efficient devices for the treatment of these disorders. The POP affects women of all ages, however, old age women are more prone to POP disorders. According to US FDA reports, the number of women who have POP is expected to increase by 46%, to 4.9 million, by 2050. According to a report published by the American Urological Association (AUA/SUFU), the prevalence of stress urinary incontinence (SUI) in women was reported to be as high as 49%. The prevalence rate of stress urinary incontinence is high in the poor nutritional status group, as it results in weakness of pelvic supports. This high prevalence rate is driving the demand for medical equipment for urinary incontinence and pelvic organ prolapse. The urinary incontinence and pelvic organ prolapse devices and equipment market are being restrained by rising health issues due to the use of vaginal mesh for the treatment of UI and POP. Regulatory agencies such as FDA and NICE have devised new guidelines for the manufacturers to address these concerns. The vaginal mesh implants generally use a Polypropylene layer over the implants. Such vaginal mesh implants containing Polypropylene have caused severe medical complications in millions of women across the world. Therefore, manufacturers are now forced to develop an alternative material, such as polyurethane, which is better suited to be used by women without any health complications for treatment of pelvic organ prolapse and urine incontinence. For instance, on October 2022, after a 36 month study on transvaginal mesh for pelvic organ prolapsed, the food and drug administration, a US-based regulator of drugs and medical devices, decided to continue its ban on transvaginal mesh due to its low risk to benefit ratio. These concerns about the safety of vaginal mesh are resulting in stringent manufacturing regulations and affecting sales, thus restraining the UI and POP devices and equipment market. The urinary incontinence and pelvic organ prolapse devices and equipment industry is characterized by the increased use of several new technologies in recent years. There is a wide range of devices being developed to treat both POP and urinary incontinence. For instance, The Lyrette transurethral SUI system led by Verathon Medical UK Ltd is the only FDA-approved treatment used for the treatment of stress urinary incontinence (SUI) among women. Devices such as Lyrette transurethral SUI system are used for procedures for incontinence. The treatment through Lyretter does not require the use of anesthesia or surgery instead, it uses radiofrequency energy to tighten the tissue of the bladder. For the treatment of POP, companies are now focusing on using native tissue prolapse repair procedures instead of vaginal mesh after the adverse health issues from the usage of vaginal mesh were highlighted. Regulatory bodies, such as the FDA in the US, regulate the manufacturing and safety guidelines for devices and equipment related to urinary incontinence and pelvic organ prolapse disorders. For instance, manufacturers are required to obtain pre-market clearance (510(k)) of the tools specifically for implanting surgical mesh. FDA requires the manufacturers in urinary incontinence and pelvic organ prolapse devices and the equipment industry to conduct post-market studies to check the specific safety and effectiveness concerns related to surgical mesh used for the repair of POP. For example, FDA regulations resulted in many companies taking down their product completely from the market and made companies like Coloplast and Acell discontinue marketing of their products- Coloplast's Restorelle DirectFix Posterior and Acell Matristem's Pelvic Floor Repair Matrix, respectively. Major players in the urinary incontinence and pelvic organ prolapse devices and equipment market are Boston Scientific Corporation, Coloplast Group, Ethicon US, C. R. Bard Inc., Johnson & Johnson, Teleflex Incorporated, Medtronic PLC., COVIDien, Cook Medical, and Neomedic. North America was the largest region in the urinary incontinence and pelvic organ prolapse devices and equipment market in 2022. Western Europe was the second largest region in the global urinary incontinence and pelvic organ prolapse devices and equipment market. The regions covered in the global urinary incontinence and pelvic organ prolapse devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the urinary incontinence and pelvic organ prolapse devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The urinary incontinence & pelvic organ prolapse devices and equipment market consist of sales of artificial urinary sphincters, electrical stimulation devices, urethral slings, and catheters that are used for the treatment of pelvic organ prolapse and urinary incontinence. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global urinary incontinence & pelvic organ prolapse devices and equipment market is segmented - 1) By Type: Urinary Incontinence Devices, Pelvic Organ Prolapse Devices 2) By Urinary Incontinence Devices: Artificial Urinary Sphincters, Electrical Stimulation Devices, Urethral Slings, Catheters 3) By Pelvic Organ Prolapse Devices: Vaginal Mesh, Vaginal Pessary 4) By Incontinence Type: Stress Incontinence, Urge Incontinence, Overflow Incontinence, Functional Incontinence 5) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Use

Nephrology and urology devices are used in the diagnosis and treatment of kidney and genitourinary diseases. The main types of nephrology and urology devices are dialysis devices and equipment, urinary stone treatment devices and equipment, urinary incontinence and pelvic organ prolapse devices and equipment, benign prostatic hyperplasia (BPH) treatment devices and equipment, and endoscopy devices and equipment. Dialysis devices and equipment is a machines used in dialysis that filter a patient's blood to remove excess water and waste products when the kidneys are damaged, dysfunctional, or missing. The dialysis machine itself is an artificial kidney. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The nephrology and urology devices market research report is one of a series of new reports from The Business Research Company that provides nephrology and urology devices market statistics, including nephrology and urology devices industry global market size, regional shares, competitors with a nephrology and urology devices market share, detailed nephrology and urology devices market segments, market trends and opportunities, and any further data you may need to thrive in the nephrology and urology devices industry. This nephrology and urology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nephrology and urology devices market grew from $17.37 billion in 2022 to $18.63 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nephrology and urology devices market is expected to grow to $23.52 billion in 2027 at a CAGR of 6.0%. The increase in the patient pool due to the rising geriatric population globally contributed significantly to the growth of the nephrology and urology devices market during the historic period. According to the World Health Organization, the number of people aged 60 years and above was 1 billion in 2020 and the number will rise to 1.4 billion by 2030 and it will reach 2.1 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. These factors increased the demand for these products and drove the market during the historic period. The nephrology and urology devices market was limited by the shortage of skilled workforce in most developed and developing countries, during the historic period. Equipment fabrication and integration require specialized skillsets relating to life sciences, pharmaceuticals, electronics, and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. This shortage of skilled labour was a significant deterrent to the growth of the market during the historic period. The nephrology and urology market is witnessing a rise in new product launches. Due to the high competition in the market, many companies are investing in advanced technologies to widen product portfolios and increase their share in the market. For instance, in March 2020, Medi-Tate an Israel-based medical device company received authorization for iTind system that is used to implant and remove nitinol devices during bladder neck remodelling. Researchers at Washington University in St. Louis, the University of Illinois at Urbana-Champaign, and Northwestern University together developed a wireless implant to control overactive bladder using LED lights. Major companies in the nephrology and urology devices market include Baxter International Inc., Fresenius Medical Care AG & Co KGaA, Cook Group Incorporated, B. Braun Group, C. R. and Bard Inc. North America was the largest region in the global nephrology and urology devices market in 2022. Asia-Pacific was the second largest region in the global nephrology and urology devices market. The regions covered in the nephrology and urology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the nephrology and urology devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The nephrology and urology devices market consist of sales of instruments such as ureteral catheters, PCN catheters, urinary stents, stone baskets, urology guidewires, and renal dilators that are used to treat kidney and genitourinary diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global nephrology and urology devices market is segmented - 1) By Type: Dialysis Devices And Equipment, Urinary Stone Treatment Devices And Equipment, Urinary Incontinence & Pelvic Organ Prolapse Devices And Equipment, Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment, Endoscopy Devices And Equipment 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

The genito-urinary drugs market consists of sales of genito-urinary drugs and related services by entities (organizations, sole traders and partnerships) that produce genito-urinary drugs to treat genito- urinary diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases. This industry includes establishments that produce infertility drugs, hormonal contraceptives, erectile dysfunction drugs and hormonal replacement drugs to treat infertility, infections and prevent pregnancy. It also consists of establishments which produce drugs for benign prostatic hypertrophy, drugs for urinary incontinence and overactive bladder, diuretics to treat urinary calculi, glomerular disorders and other urinary disorders. The main types of genito-urinary drugs are hormonal contraceptives, drugs for benign prostatic hypertrophy, drugs for infertility, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infections and others, drugs for hormonal replacement therapy and diuretics. Hormonal contraceptives are medications or devices that reduce the likelihood of becoming pregnant. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global genito-urinary drugs market size is expected to grow from $40.40 billion in 2021 to $42.75 billion in 2022 at a compound annual growth rate (CAGR) of 5.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The genito-urinary drugs market is expected to reach $63.83 billion in 2026 at a CAGR of 10.5%. The aging population profile of most countries contributed to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, contributed significantly to the growth of the market during the historic period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This has led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the genito-urinary drugs industry in the historic period. Pharmaceutical companies are investing in development of new class drugs for treating overactive bladders (OAB). Earlier anti-muscarinic agents have been used for the treatment of OAB. Going forward, the market is expected to be driven by a new class of drug known as beta-3 adrenergic agonists that has been increasingly used to treat OAB. Beta-3 adrenergic agonists are drugs which cause the bladder muscles to relax without causing side effects such as dry mouth. For instance, In December 2019, GEMTESA's new drug application (NDA) was submitted to the US Food and Drug Administration (FDA), and it was accepted for review in March 2020. GEMTESA ® is a beta-3 adrenergic agonist used to treat overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. Major companies in the genito-urinary drugs market include Sanofi S.A, GlaxosmithKline, AstraZeneca, AbbVie, Reckitt, Benckiser Group plc, Astellas Pharma Inc., Otsuka Holdings Co ltd, Pfizer Inc., Merck KGaA and Daiichi Sankyo Company. North America was the largest region in the genito-urinary market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the genito-urinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global genito-urinary drugs market is segmented - 1) By Type: Hormonal Contraceptives, Drugs for Benign Prostatic Hypertrophy, Drugs for Infertility, Drugs for Erectile Dysfunction, Drugs for Urinary Incontinence and Overactive Bladder, Drugs for Infections and Others, Drugs for Hormonal Replacement Therapy, Diuretics 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs